PDCD1 and post-transplant lymphoproliferative disease: However, immune-checkpoint blockade in transplant recipients is a delicate task due to the risk of transplant rejection, an issue that currently limits the utilization of anti-PD-1 and anti-PD-L1 antibodies in PTLD patients [53,54].